Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Just For You
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Submitted by Jeffrey Neal Johnson. Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes the company’s recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. The sharp downturn has prompted questions about whether the foundation of this industry leader is cracking. A closer look suggests a potential disconnect between market sentiment and operational reality. The key question: is the market’s pessimism justified, or has a value opportunity emerged for long-term investors? Separating Signal From NoiseAbbott’s decline has two distinct drivers. First, an internal headwind: the Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales drop in Nutrition, largely due to U.S. pediatric market-share losses and pricing dynamics that weighed on volumes. Management has acknowledged the issues and outlined a turnaround plan. CEO Robert B. Ford pointed to price and promotion initiatives and at least eight new product launches in 2026, forecasting a return to growth in the second half of the year. The second factor is broader and external: a market rotation. As investors chase higher returns during periods of economic optimism, capital often moves out of defensive sectors like healthcare and into higher-beta areas such as artificial intelligence and the energy sector. This trend has weighed on many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition navigates a short-term recovery, Abbott’s core businesses remain robust—led by its largest and most profitable division, Medical Devices. That segment accelerated to 10.4% organic growth in the most recent quarter, offsetting the isolated weakness in Nutrition.
Medical Devices: The segment is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth engine. The product, which lets users monitor glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and continues to be a primary contributor to Abbott’s top line. Cardiovascular Leadership: Abbott is strong in cardiovascular care. Its Electrophysiology business grew at a double-digit pace, while Structural Heart posted 8.7% organic growth. The company’s portfolio includes best-in-class solutions such as MitraClip and TriClip, and recent approvals like the Volt PFA System expand its innovation pipeline for treating atrial fibrillation. Abbott is also pursuing external growth. Its planned acquisition of Exact Sciences—a leader in cancer screening and diagnostics best known for the Cologuard test—would immediately position Abbott in the rapidly expanding market for cancer diagnostics, adding a high-growth vertical with significant revenue potential. Analysts appear to share the optimistic view. Wall Street maintains a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47, implying upside of more than 30% from current levels. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a key attraction. Abbott is a member of the S&P 500 Dividend Kings—companies that have increased their dividend for at least 50 consecutive years—underscoring a deep commitment to returning capital through market cycles. The recent drop in Abbott’s stock price has a direct upside for new investors: a higher yield. At current levels, Abbott yields about 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend appears secure: the payout ratio is about 68% of earnings and represents roughly 37% of cash flow, showing Abbott generates ample cash to cover distributions with room for increases. A Disconnect Between Price and ValueCurrent market sentiment seems out of step with Abbott’s business reality. Temporary headwinds in one division and broader market rotations have pressured the stock, even as its core growth engines accelerate. Medical Devices continues to perform strongly, the dividend remains a dependable income source, and catalysts such as the Exact Sciences acquisition could drive meaningful future growth. For long-term investors, the present valuation suggests a gap between price and fundamental value that may present a compelling opportunity. |
